Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci

被引:142
作者
Malley, R
Lipsitch, M
Stack, A
Saladino, R
Fleisher, G
Pelton, S
Thompson, C
Briles, D
Anderson, P
机构
[1] Harvard Univ, Sch Publ Hlth, Childrens Hosp, Dept Med,Div Infect Dis, Boston, MA 02115 USA
[2] Harvard Univ, Sch Publ Hlth, Childrens Hosp, Dept Med,Div Emergency Med, Boston, MA 02115 USA
[3] Boston Med Ctr, Div Pediat Infect Dis, Boston, MA USA
[4] Boston Univ, Boston, MA 02215 USA
[5] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA
[6] Univ Rochester, Dept Pediat, Rochester, NY USA
关键词
D O I
10.1128/IAI.69.8.4870-4873.2001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A whole-cell killed unencapsulated pneumococcal vaccine given by the intranasal route with cholera toxin as an adjuvant was tested in two animal models. This vaccination was highly effective in preventing nasopharyngeal colonization with an encapsulated serotype 6B strain in mice and also conferred protection against illness and death in rats inoculated intrathoracically with a highly encapsulated serotype 3 strain. When the serotype 3 challenge strain was incubated in the sera of immunized rats, it was no longer virulent in an infant-rat sepsis model, indicating that the intranasal immunization elicited protective systemic antibodies. These studies suggest that killed whole-cell unencapsulated pneumococci given intranasally with an adjuvant may provide multitypic protection against capsulated pneumococci.
引用
收藏
页码:4870 / 4873
页数:4
相关论文
共 28 条
[1]  
[Anonymous], 1998, Wkly Epidemiol Rec, V73, P187
[2]   CONTRIBUTION OF AUTOLYSIN TO VIRULENCE OF STREPTOCOCCUS-PNEUMONIAE [J].
BERRY, AM ;
LOCK, RA ;
HANSMAN, D ;
PATON, JC .
INFECTION AND IMMUNITY, 1989, 57 (08) :2324-2330
[3]   Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children [J].
Black, S ;
Shinefield, H ;
Fireman, B ;
Lewis, E ;
Ray, P ;
Hansen, JR ;
Elvin, L ;
Ensor, KM ;
Hackell, J ;
Siber, G ;
Malinoski, F ;
Madore, D ;
Chang, I ;
Kohberger, R ;
Watson, W ;
Austrian, R ;
Edwards, K .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) :187-195
[4]   Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults [J].
Boyce, TG ;
Hsu, HH ;
Sannella, EC ;
Coleman-Dockery, SD ;
Baylis, E ;
Zhu, YW ;
Barchfeld, O ;
DiFrancesco, A ;
Paranandi, M ;
Culley, B ;
Neuzil, KM ;
Wright, PF .
VACCINE, 2000, 19 (2-3) :217-226
[5]   PspA, a protection-eliciting pneumococcal protein: Immunogenicity of isolated native PspA in mice [J].
Briles, DE ;
King, JD ;
Gray, MA ;
McDaniel, LS ;
Swiatlo, E ;
Benton, KA .
VACCINE, 1996, 14 (09) :858-867
[6]   ANTI-PHOSPHOCHOLINE ANTIBODIES FOUND IN NORMAL MOUSE SERUM ARE PROTECTIVE AGAINST INTRAVENOUS INFECTION WITH TYPE-3 STREPTOCOCCUS-PNEUMONIAE [J].
BRILES, DE ;
NAHM, M ;
SCHROER, K ;
DAVIE, J ;
BAKER, P ;
KEARNEY, J ;
BARLETTA, R .
JOURNAL OF EXPERIMENTAL MEDICINE, 1981, 153 (03) :694-705
[7]  
Briles DE, 2000, EFFECTS OF MICROBES ON THE IMMUNE SYSTEM, P263
[8]   Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA [J].
Briles, DE ;
Hollingshead, SK ;
King, J ;
Swift, A ;
Braun, PA ;
Park, MK ;
Ferguson, LM ;
Nahm, MH ;
Nabors, GS .
JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (06) :1694-1701
[9]  
Brooks-Walter A, 1999, INFECT IMMUN, V67, P6533
[10]  
BULL C, 1929, J HOPKINS B PUBLIC H, P490